Gender differences in HIV progression to AIDS and death in industrialized countries: Slower disease progression following HIV seroconversion in women

American Journal of Epidemiology

Volumn 168, Issue 5, 2008, Pages 532-540

  Jarrin, Inmaculada ^a,b,c   Geskus, Ronald ^d,e,z   Bhaskaran, Krishnan ^f,n   Prins, Maria ^d,g,n,z   Perez Hoyos, Santiago ^c,h,ah   Muga, Roberto ^i,n,ae   Hernández Aguado, Ildefonso ^b,c,ah   Meyer, Laurence ^j,k,l,n,v   Porter, Kholoud ^f,n,an   Amo, Julia Del ^a,c,m   Bucher, Heiner ^n,ai   Chêne, Geneviève ^n,s   Pillay, Deenan ^n,n,ao   Rosinska, Magda ⁿ   Sabin, Caroline ^n,n,am   Touloumi, Giota ^n,n,x   del Amo, Julia ^n,ag   Walker, Sarah ⁿ   Babiker, Abdel ^n,an   Darbyshire, Janet ^n,an   de Luca, Andrea ⁿ   Fisher, Martin ⁿ   Goujard, Cécile ⁿ   Kaldor, John ^o   Kelleher, Tony ^o   Gelgor, Linda ^o   Ramacciotti, Tim ^o   Cooper, David ^o   Smith, Don ^o   Gill, John ^p   Bruun Jørgensen, Louise ^q   Nielsen, Claus ^q   Pedersen, Court ^q   Lutsar, Irja ^r   Dabis, Francois ^s   Thiebaut, Rodolphe ^s   Masquelier, Bernard ^s   Costagliola, Dominique ^t   Vanhems, Philippe ^u   Boufassa, Faroudy ^v   Hamouda, Osamah ^w   Kucherer, Claudia ^w   Pantazis, Nikos ^x   Hatzakis, Angelos ^x   Paraskevis, Dimitrios ^x   Karafoulidou, Anastasia ^x   Rezza, Giovanni ^y   Dorrucci, Maria ^y   Longo, Benedetta ^y   Balotta, Claudia ^y   van Asten, Liselotte ^z   van der Bij, Akke ^z   Coutinho, Roel ^z   Sannes, Mette ^aa   Brubakk, Oddbjorn ^aa   Eskild, Anne ^aa   Bruun, Johan N ^aa   Rosinska, Magdalena ^ab   Camacho, Ricardo ^ac   Smolskaya, Tatyana ^ad   Tor, Jordi ^ae   de Olalla, Patricia Garcia ^af   Caylà, Joan ^af   del Romero, Jorge ^ag   Belda, Josefina ^ah   Rickenbach, Martin ^ai   Francioli, Patrick ^ai   Malyuta, Ruslan ^aj   Brettle, Ray ^ak   Delpech, Valerie ^al,an   Lattimore, Sam ^al   Murphy, Gary ^al   Parry, John ^al   Gill, Noel ^al   Lee, Christine ^am   Johnson, Anne ^an   Phillips, Andrew ^an   Jaffe, Harold ^ap   more..

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f MEDICAL RESEARCH COUNCIL   (United Kingdom)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h Generalitat Valenciana   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j INSERM   (France)

^k UNIVERSITÉ PARIS SACLAY   (France)

^l BICÊTRE HOSPITAL   (France)

^m UNIVERSIDAD REY JUAN CARLOS   (Spain)

ⁿ Sydney AIDS Prospective Study and Sydney Primary HIV Infection cohort ^*

^o Sydney Primary HIV Infection Cohort   (Australia)

^p South Alberta Clinic   (France)

^q Tartu Ülikool ^*  (Denmark)

^r UNIVERSITY OF TARTU   (Estonia)

^s Aquitaine cohort   (France)

^t French Hospital Database   (France)

^u Lyon Primary Infection Cohort   (France)

^v SEROCO cohort   (France)

^w German cohort   (Germany)

^x Greek Haemophilia Cohort   (Greece)

^y Italian Seroconversion Study   (Italy)

^z Amsterdam Cohort Studies Among Homosexual Men and Drug Users   (Netherlands)

^aa ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^ab NATIONAL INSTITUTE OF HYGIENE   (Poland)

^ac UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^ad Pasteur Institute   (Russian Federation)

^ae Badalona IDU Hospital Cohort   (Spain)

^af Barcelona IDU Cohort   (Spain)

^ag Madrid Cohort   (Spain)

^ah Valencia IDU cohort   (Sweden)

^ai Swiss HIV cohort   (Switzerland)

^aj Perinatal Prevention of AIDS Initiative   (Ukraine)

^ak Edinburgh Hospital Cohort   (United Kingdom)

^al PUBLIC HEALTH ENGLAND   (United Kingdom)

^am Royal Free hemophilia cohort   (United Kingdom)

^an UK Register of HIV Seroconverters   (United Kingdom)

^ao UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ap UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy, highly active; Cohort studies; Death; Disease progression; HIV; Sex

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; INDUSTRIAL LOCATION; MORTALITY; SEX-RELATED DIFFERENCE; WOMENS HEALTH;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; COHORT ANALYSIS; DEATH; DEVELOPED COUNTRY; DISEASE COURSE; FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; KAPOSI SARCOMA; LUNG TUBERCULOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; SEROCONVERSION; SEX DIFFERENCE; SEXUAL INTERCOURSE; STATISTICAL SIGNIFICANCE;

AUSTRALASIA; AUSTRALIA; CANADA; EURASIA; EUROPE; NORTH AMERICA;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 50649116552     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn179     Document Type: Article

References (42)

1. Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005;19:357-70.
2. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ 1994;309:1537-42.
3. von Overbeck J, Egger M, Smith GD, et al. Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. AIDS 1994;8:1307-13.
4. Pezzotti P, Galai N, Vlahov D, et al. Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:275-82.
5. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999;13:2361-4.
6. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS incubation and HIV survival including the CASCADE EU Concerted Action. Lancet 2000;355:1131-7.
7. AIDS incubation period in Spain before highly active antiretroviral therapy. (In Spanish). Med Clin (Barc) 2000;115:681-6.
8. Lemp GF, Hirozawa AM, Cohen JB, et al. Survival for women and men with AIDS. J Infect Dis 1992;166:74-9.
9. Friedland GH, Saltzman B, Vileno J, et al. Survival differences in patients with AIDS. J Acquir Immune Defic Syndr 1991;4:144-53.
10. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994;272:1915-21.
11. Phillips AN, Antunes F, Stergious G, et al. A sex comparison of rates of new AIDS defining disease and death in 2554 AIDS cases. AIDS 1994;8:831-5.
12. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15:1115-23.
13. Hessol NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007;44:287-94.
14. Hubert JB, Rouzioux C, Boufassa F, et al. Gender, disease progression and response to HAART. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. (Abstract ThOrC1448).
15. Perez-Hoyos S, del Amo J, Muga R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003;17:353-9.
16. Pezzotti P, Dorrucci M, Donisi A, et al. Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART). Epidemiol Prev 2003;27:348-55.
17. Porter K, Babiker A, Bhaskaran K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-74.
18. Garcia de la Hera M, Ferreros I, del Amo J, et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 2004;58:944-50.
19. CASCADE (Concerted Action on Seroconversion to AIDS and Death in Europe) Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000;1:224-31.
20. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993;341:441.
21. Clayton C, Hills M. Statistical models in epidemiology. Oxford, United Kingdom: Oxford University Press, 1993.
22. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley & Sons, 1990.
23. Andersen PK, Borgan O, Gill RD, et al. Statistical models based on counting processes. New York, NY: Springer Verlag, 1993.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
25. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks andmulti-stagemodels. Stat Med 2007;26:2389-430.
26. Babiker A, Darbyshire J, Pezzotti P, et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002;31:951-8.
27. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006;20:741-9.
28. StataCorp. Stata Statistical Software, release 7.0. College Station, TX: Stata Corporation, 2001.
29. Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998;2:96-104.
30. The GLOBOCAN 2002 database. Cancer incidence, mortality and prevalence worldwide. (http://www-dep.iarc.fr/globocan/database.htm). (Accessed June 30, 2007).
31. Blehar MC. Public health context of women's mental health research. Psychiatr Clin North Am 2003;26:781-99.
32. Moore AL, Sabin CA, Johnson MA, et al. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002;29:197-202.
33. Smith DK, Gardner LI, Phelps R, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health 2003;80:676-88.
34. Waldron I. Recent trends in sex mortality ratios for adults in developed countries. Soc Sci Med 1993;36:451-62.
35. Wingard DL. The sex differential in morbidity, mortality, and lifestyle. Annu Rev Public Health 1984;5:433-58.
36. Federman DD. The biology of human sex differences. N Engl J Med 2006;354:1507-14.
37. Patsopoulos NA, Tatsioni A, Ioannidis JPA. Claims of sex differences. An empirical assessment in genetic associations. JAMA 2007;298:880-93.
38. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510-14.
39. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720-5.
40. Nicastri E, Angeletti C, Palmisano L, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005;19:577-83.
41. Berg KM, Demas PA, Howard AA, et al. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004;19:1111-17.
42. Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 2006;42:554-61.